Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

In a pooled analysis of data collected from invasive pneumococcal disease surveillance databases, Daniel Feikin and colleagues examine serotype replacement after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs. Please see later in the article for the Editors' Summary

[1]  T. J. Mitchell,et al.  Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010. , 2014, Vaccine.

[2]  D. Goldblatt,et al.  Pediatric Invasive Pneumococcal Disease Caused by Vaccine Serotypes following the Introduction of Conjugate Vaccination in Denmark , 2013, PloS one.

[3]  T. Kilpi,et al.  Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial , 2012, The Lancet.

[4]  H. D. de Melker,et al.  Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands , 2012, Emerging infectious diseases.

[5]  D. Greenberg,et al.  Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. , 2012, Vaccine.

[6]  E. Emini,et al.  The 13-Valent Pneumococcal Conjugate Vaccine for Invasive Pneumococcal Disease in Alaska Native Children: Results of a Clinical Trial , 2012, The Pediatric infectious disease journal.

[7]  V. Krause,et al.  Invasive pneumococcal disease in Australia 2007 and 2008. , 2012, Communicable diseases intelligence quarterly report.

[8]  K. Mulholland,et al.  Serotype replacement after pneumococcal vaccination , 2012, The Lancet.

[9]  M. Lipsitch,et al.  The Prevalence and Risk Factors for Pneumococcal Colonization of the Nasopharynx among Children in Kilifi District, Kenya , 2012, PloS one.

[10]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[11]  N. Andrews,et al.  Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. , 2011, Vaccine.

[12]  N. Andrews,et al.  Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. , 2011, The Lancet. Infectious diseases.

[13]  M. Ploy,et al.  Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[14]  J. Verhaegen,et al.  Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. , 2011, Vaccine.

[15]  N. Andrews,et al.  Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study , 2011, PLoS medicine.

[16]  M. Lipsitch,et al.  Prediction of Serotypes Causing Invasive Pneumococcal Disease in Unvaccinated and Vaccinated Populations , 2011, Epidemiology.

[17]  W. Schaffner,et al.  Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization , 2010, AIDS.

[18]  S. Cotter,et al.  Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland , 2010, Epidemiology and Infection.

[19]  W. Schaffner,et al.  Risk Factors for Invasive Pneumococcal Disease in Children in the Era of Conjugate Vaccine Use , 2010, Pediatrics.

[20]  C. Mathers,et al.  Global, regional, and national causes of child mortality in 2008: a systematic analysis , 2010, The Lancet.

[21]  K. O'Brien,et al.  Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Lipsitch,et al.  The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. , 2010, Vaccine.

[23]  S. Black.  The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. , 2009, The Pediatric infectious disease journal.

[24]  T. Cherian,et al.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates , 2009, The Lancet.

[25]  O. Vanderkooi,et al.  Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Beek.  Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis , 2010 .

[27]  D. Greenberg,et al.  Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. , 2009, The Journal of infectious diseases.

[28]  J. Treanor,et al.  Differential effects of pneumococcal vaccines against serotypes 6A and 6C. , 2008, The Journal of infectious diseases.

[29]  Rosanna Lagos,et al.  Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994--2007. , 2008, The Journal of infectious diseases.

[30]  P. Kriz,et al.  Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997–2006 , 2008, Epidemiology and Infection.

[31]  D. Caugant,et al.  Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. , 2008, Vaccine.

[32]  K. O'Brien,et al.  Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. , 2007, The Journal of infectious diseases.

[33]  E. Lewis,et al.  Surveillance for Invasive Pneumococcal Disease During 2000–2005 in a Population of Children Who Received 7-Valent Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[34]  J. Morgan,et al.  Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance , 2007, Epidemiology and Infection.

[35]  L. Hammitt,et al.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. , 2007, JAMA.

[36]  T. Peto,et al.  Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. , 2006, The Journal of infectious diseases.

[37]  C. Byington,et al.  Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  D. Feikin,et al.  Epidemiological differences among pneumococcal serotypes. , 2005, The Lancet. Infectious diseases.

[39]  Richard Platt,et al.  Post-PCV7 Changes in Colonizing Pneumococcal Serotypes in 16 Massachusetts Communities, 2001 and 2004 , 2004, Pediatrics.

[40]  B. Spratt,et al.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. , 2004, The Journal of infectious diseases.

[41]  Alexander J Sutton,et al.  What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.

[42]  G. Daikos,et al.  Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children , 2004, European Journal of Pediatrics.

[43]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[44]  D. Feikin,et al.  Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[46]  G. Siber,et al.  Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children , 2001, The Lancet.

[47]  V. Krause,et al.  Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998 , 2000, The Medical journal of Australia.

[48]  Pneumococcal vaccines WHO position paper--2012. , 2012, Releve epidemiologique hebdomadaire.

[49]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[50]  Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. , 2010, Releve epidemiologique hebdomadaire.

[51]  K. Krogfelt,et al.  Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  David Coleman,et al.  INVASIVE PNEUMOCOCCAL DISEASE IN AUSTRALIA , 2007 .

[53]  R. Martorell,et al.  Effectiveness of vitamin A supplementation in the control of young child morbidity and mortality in developing countries. Revised ed. , 1993 .

[54]  A. Fenoll,et al.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. , 1991, Reviews of infectious diseases.

[55]  C. Cox.  Fieller's theorem, the likelihood and the delta method , 1990 .